ECGI in Patients With Persistent Atrial Fibrillation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-02-23

Study Completion Date

2022-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the values and limitations of ECGI in guiding ablation and risk stratification in patients with persistent atrial fibrillation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

HD Mapping of Atrial Fibrillation in Asia Pacific

NCT04022954

Paroxysmal Atrial Fibrillation Persistent Atrial Fibrillation

COMPLETED

Analysis of Endocavitary Electrical Signal and Surface Electrocardiogram to Predict Ablation Outcome in Persistent Atrial Fibrillation

NCT03937089

Atrial Fibrillation

COMPLETED

AF-FLOW Registry to Evaluate Electrographic Flow Mapping in Patients Undergoing Ablation for Atrial Fibrillation

NCT05481359

Atrial Fibrillation, Persistent Atrial Fibrillation Arrhythmias, Cardiac +1 more

COMPLETED

The Role of Right Atrial Ectopy Triggering Ganglionated Plexuses in AF

NCT05539040

Cardiac Arrhythmia Atrial Fibrillation

RECRUITING NA

Signal Transfer of Atrial Fibrillation Data to Guide Human Treatment

NCT01765075

Permanent Atrial Fibrillation

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The patient population will include symptomatic persistent AF patients (N=50). The total of fifty patients will be studied to determine:

* The values and limitations of ECGI in identifying atrial fibrillation (AF) triggers, AF initiators and AF perpetuators as targets sites for catheter ablations in patients with persistent AF.
* The mechanisms of residual atrial tachycardia/flutter (Res-AT/AFl) after AF substrate ablations by targeting complex fractionated atrial electrograms (CFAE).
* If there is a relationship between primary CFAE sites and driver sites or other distinct patterns from the ECGI mapping system.
* The rate of AF termination to sinus rhythm after ablation at target sites identified by ECGI

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radiofrequency ablation

RF applications were delivered with a maximal temperature of 43°C at the catheter tip (SmartTouch Navistar Thermocool catheter) and at the power between 25-50 watts. The primary end points during RF ablation were either complete elimination of areas with CFAE or conversion of AF to normal sinus rhythm (SR). When areas with CFAE were completely eliminated but the atrial arrhythmias persisted (organized atrial flutter or atrial tachycardia), they were subsequently mapped and ablated (occasionally in conjunction with ibutilide, 1 - 2 mgs intravenously over 10 minutes).

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients are diagnosed as persistent AF. Persistent AF was defined as continuous AF from 7 days to 12 months and long- lasting AF beyond twelve months.
* Patients who are symptomatic
* Patients who are willing to sign consent and be followed post procedure in an out- patient arrhythmia clinic

Exclusion Criteria

* Patients under 18 years or over 85 years of age.
* Patients with chronic alcoholism.
* Recent myocardial infarction within one month of the study.
* Significant debilitating diseases or a terminal disease.
* Patients with documented left atrial thrombus.
* Medical or mental conditions precluding a long-term follow-up.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No